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Combined Chemotherapy and Radiotherapy for Patients
With Breast Cancer and Extensive Nodal Involvement
By Owen Ung, Allan O. Langlands, Bruce Barraclough, and John Boyages
Purpose: This retrospective review examines local
control, feedom from distant failure, and survival for
patients with nonmetastatic breast cancer with extensive
nodal disease (> 10 nodes, 45 patients; or _ 70% in-
volved nodes if < 10 nodes found, 19 patients). All pa-
tients received chemotherapy and radiotherapy follow-
ing mastectomy.
Patients and Methods: Sixty-four patients were
treated between January 1980 and December 1988 at
Westmead Hospital, Westmead, NSW Australia. The
median follow-up duration for surviving patients was
91.5 months (range, 56 to 121). The median age was 51
years, and the median number of positive nodes was
11. Four successive protocols evolved, each with three
phases, as follows: induction chemotherapy (doxorubi-
cin or mitoxantrone, plus cyclophosphamide; three cy-
cles), radiotherapy (50 Gy in 25 fractions to chest wall
and regional nodes), then chemotherapy (cyclophospha-
mide, methotrexate, and fluorouracil [CMF]) of progres-
sively shorter duration. Radiotherapy and chemotherapy
T HE OPTIMUM management of patients with exten-
sive nodal involvement following total mastectomy
is undefined and has evolved with the recognition that
such patients are at high risk not only for local recurrence,
but also for distant relapse and death. The definition of
patients with extensive nodal involvement has varied
from a high absolute number (usually Ž 10) to a high
percentage of the number of nodes dissected being posi-
tive.' However, the extent of histologic involvement of
the axillary nodes is dependent on the type of surgery
performed and the extent of the pathologic analysis of
the axillary specimen. Most clinicians define patients with
- 10 involved nodes to be at high risk, but it is unclear
what constitutes extensive involvement if fewer than 10
nodes are dissected and/or fewer than 10 nodes are identi-
fied by the pathologist.
Data on the natural history of 24,136 women with ex-
tensive nodal involvement who were treated before 1972
with mastectomy with or without adjuvant radiation ther-
apy is available from a national survey by the American
College of Surgeons.2 The risk of locoregional recurrence
and death increased as the number of positive nodes in-
creased. There was no clear dividing point by the absolute
number of involved nodes. Patients with more than 10
positive nodes constituted 14% of all patients with posi-
tive nodes. The 5-year absolute survival rate in this group
was 18.5%. Donegan and Lewis3 also found that the num-
ber of positive nodes represented a continuum of increas-
were concurrent in the fourth regimen.
Results: One patient (1.5%) developed local recur-
rence -fore distant relapse, and seven patients (11%)
developed local and/or regional recurrence simultane-
ously or after distant relapse. The 5-year actuarial free-
dom from distant relapse and overall survival rates were
45% and 65%, respectively. Overall survival did not vary
significantly by menopausal status, nodal subgroup, or
dose-intensity. There were no treatment-related deaths.
Conclusion: Combined chemotherapy and radiother-
apy in standard dosage is an acceptable approach fol-
lowing mastectomy for patients with extensive nodal
involvement at high risk for local recurrence and distant
relapse. This approach should be considered standard
best therapy for any randomized trials that examine
high-dose chemotherapy or bone marrow transplanta-
tion for this subgroup of patients.
J Clin Oncol 13:435-443. © 1995 by American So-
ciety of Clinical Oncology.
ing risk for treatment failure. In their study of 801 cases
of breast cancer treated by radical mastectomy, patients
with more than 10 involved nodes had a local recurrence
rate of approximately 50% and a 10-year survival rate of
less than 10%.
During the mid-1970s, the first results of adjuvant
multiagent chemotherapy following mastectomy began to
show significant improvements in disease-free survival.
The recognition that adjuvant radiotherapy increased
morbidity without an improvement of overall survival
resulted in a diminution of its use, even in cases consid-
ered at high risk of local recurrence.4 Several subsequent
randomized studies showed a benefit for the addition of
radiotherapy to chemotherapy after mastectomy.5 -13 Most
of these studies reported a reduction in the risk of local
recurrence and an improvement in disease-free survival.
The largest study also found a survival advantage for
adjuvant radiation and chemotherapy."
The poor prognosis of patients with extensive nodal
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disease has promoted the use of adjuvant dose-intensive
chemotherapyl5"6 or the use of high-dose chemotherapy
with autologous bone marrow transplant."5 '""' Initial re-
sults have demonstrated a possible improvement in dis-
ease-free survival. However, there are a number of cave-
ats, including small numbers of patients, short follow-up
periods, and selection of younger and fitter premeno-
pausal patients for these studies. Extensive pretreatment
staging in the most recent trials of adjuvant chemotherapy
or autologous bone marrow transplantation may explain
the improvement of results with time. Any improvement
in disease-free survival and possible overall survival from
newer approaches must be balanced against increased
morbidity, mortality, and cost.
In this report, we update the results of a series of pa-
tients with extensive nodal disease treated at Westmead
Hospital with combined chemotherapy and radiotherapy
in standard doses after total mastectomy and axillary dis-
section. Isolated local recurrence was rare, and acceptable
rates of 5-year distant disease-free survival and overall
survival were achieved for both premenopausal and post-
menopausal patients. Our results are comparable to less
mature results of high-dose chemotherapy with or without
bone marrow transplantation and were achieved with min-
imal morbidity and no treatment-related mortality. This
approach should be considered standard best therapy for
randomized trials investigating high-dose chemotherapy




Between January 1980 and December 1988, 64 patients with non-
metastatic breast cancer with extensive nodal involvement were
treated with combined chemotherapy and radiotherapy following
total mastectomy at the Department of Radiation Oncology, West-
mead Hospital, Westmead, Australia. The median age for the patient
group was 51 years (range, 24 to 72) and 49% of patients were
premenopausal or perimenopausal.
Extensive nodal disease was defined as T1, T2, or T3 tumor (1978
International Union Against Cancer [UICC] staging system) without
evidence of metastatic disease in a patient with 2- 10 axillary lymph
nodes involved (45 patients) or a 70% involvement if fewer than
10 nodes were identified following an axillary dissection (19 pa-
tients). The median tumor size was 4 cm (range, 2 to 10). The
number of nodes dissected ranged from four to 36 (median, 17) and
the median number of positive nodes was 11 (range, three to 26).
All patients underwent a metastatic evaluation that consisted of a
blood count, routine blood chemistries, a chest x-ray, and bone scan
and/or liver ultrasound if indicated by abnormalities in serum alka-
line phosphatase or liver renal enzymes. Patients were excluded if
they had significant cardiac or respiratory comorbidity (two patients)
or if they were older than 75 years of age.
Treatment
All patients had undergone total mastectomy and axillary dissec-
tion. Treatment consisted of three cycles of induction chemotherapy,
followed by locoregional radiotherapy then progressively shorter
courses of additional chemotherapy. Four regimens evolved over the
study period, with the aim to reduce the overall treatment time and
treatment morbidity.
Phase 1 consisted of three cycles of either doxorubicin (50 mg/
m2; regimens 1 and 2) or since mid-1987, mitoxantrone (12 mg/m2)
combined with cyclophosphamide (750 mg/m2; regimens 3 and 4)
administered intravenously on day 1 of a 21-day cycle.
Phase 2 of treatment involved radiotherapy, of which all patients
received 6-MV photons to the chest wall, supraclavicular fossa, and
axilla. Typically, 50 Gy was delivered in 2-Gy fractions to the breast
by medial and lateral tangential fields, using wedges to correct for
inhomogeneity over 5 % weeks. The ipsilateral supraclavicular fossa
and axilla were treated by an anterior field, prescribing 50 Gy in 25
fractions at 1.5 cm depth to the supraclavicular fossa. A posterior
axillary boost was used to prescribe 50 Gy in 25 fractions to the
midplane of the axilla. The internal mammary nodes were not rou-
tinely irradiated. One centimeter of bolus to the skin of the chest
wall was used on a daily or second-daily basis for 70% of patients.
Phase 3 consisted of progressively shorter courses of cyclophos-
phamide (600 mg/m2), methotrexate (40 mg/m2), and fluorouracil
(600 mg/m2) (CMF), usually administered intravenously on a 3-
week cycle. Eleven patients who received regimen 1 were given oral
cyclophosphamide (100 mg/m2 on days 1 to 14), methotrexate (40
mg/m2 on days 1 and 8), and fluorouracil (600 mg/m2 on days 1 and
8) on a 4-week cycle for 12 courses as previously reported.' A
reduction to six cycles of intravenous CMF (regimen 2, 20 patients;
regimen 3, 13 patients) was based on an Italian study'9 that examined
CMF in the adjuvant setting. Our results of intravenous versus oral
CMF are published elsewhere. 20 The reduction to three cycles, given
synchronously with radiotherapy (regimen 4, 20 patients), was em-
pirical. The overall treatment time was reduced from a minimum of
50 weeks (regimen 1) to 18 weeks (regimen 4). Tamoxifen 20 mg/
d was given for 2 years starting with the first cycle of chemotherapy
to patients whose tumors were estrogen receptor-positive. Blood
counts were performed before each course of chemotherapy and
weekly during radiotherapy.
Follow-Up Evaluation
Follow-up data were obtained to June 1993. The median follow-
up duration for surviving patients was 91.5 months (range, 56 to
121 m). Twenty-seven of 32 surviving patients (84%) had a follow-
up duration - 60 months and all patients were monitored for at
least 56 months. Two patients with documented metastatic disease
were lost to follow-up at 9 and 29 months, respectively. Patients
who remained disease-free were reviewed every 3 months for the
first 2 years, every 6 months for the next 3 years, and annually
thereafter. Apart from yearly mammograms for the contralateral
breast, investigations were not performed routinely, but on the basis
of symptoms.
Statistical Methods
Local recurrence was defined as recurrent disease in the ipsilateral
chest wall or regional lymph nodes. Local recurrence was scored
even when it occurred after a distant relapse. Crude and actuarial
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rates of local recurrence were calculated. Differences in rates of
local recurrence were compared using the combined binomial exact
test (CBET).21 Local recurrence was scored as occurring concur-
rently with distant relapse if it was detected within 2 months of
distant relapse. Actuarial rates of freedom from distant failure (FDF)
and overall survival were calculated using the method of Kaplan
and Meier. 2 2 Differences were compared using the log-rank test. 23
The most common sites of distant relapse were bone (45%), lung
and pleura (29%), and liver (11%). Three patients with contralateral
breast cancer and two patients with contralateral axillary disease
were scored as having a distant relapse. The probability of distant
relapse was examined by nodal subgroup (> 10 nodes v - 70%
involvement if < 10 nodes identified) and by menopausal status.
Postmenopausal patients were defined as those - 50 years of age
at diagnosis. Death from all causes was scored as an event for
survival analysis. Two patients died from causes other than breast
cancer while disease-free. Subgroup analyses of the risk of distant
relapse and survival were calculated separately by age at diagnosis
(< 50 years v - 50 years) and nodal status (> 10 positive nodes or
- 70% involved nodes). P values - .05 were considered statistically
significant. Time to recurrence and follow-up times were calculated
from the date of mastectomy. The influence of dose-intensity was
examined using total doses of cyclophosphamide, as this was given
in both phases of chemotherapy using the method reported by Hry-
niuk and Levine. 24 However, dose-intensity was not associated with
the risk of distant relapse (results not shown). Toxicity for each
phase of treatment was evaluated for all patients according to the
World Health Organization (WHO) classification.
Complications of treatment were abstracted from the radiotherapy
and chemotherapy records. Data collected included information on
leukopenia, alopecia, symptomatic pneumonitis, and arm edema.
Minimal, moderate, or severe arm edema was arbitrarily set at a
difference of 0.5 to 2 cm, 2.1 to 4.0 cm, and greater than 4.0 cm in
girth between the treated and untreated side, usually measured 10
cm above the olecranon.
RESULTS
After a median follow-up duration of 91.5 months,
eight patients (12.5%) have developed local recurrence.
Seventy-five percent of local recurrences occurred within
30 months and all occurred within 48 months after mas-
tectomy. Concurrent local recurrence and distant relapse
occurred in four patients, distant first then local in three
patients, and local followed by distant in only one patient
(1.5%). For six of eight patients, local recurrence was
minor and asymptomatic. Local recurrence generally oc-
curred in the scar or chest wall and consisted of small
nodules. One patient was noted to have small axillary
nodules and three patients had supraclavicular masses.
All of these nodules were controlled by local excision
and/or hormonal treatment. Two patients developed un-
controlled local recurrence. A 54-year-old woman, who
developed metastatic disease concurrently, died with a
supraclavicular mass and carcinoma en curraise. The
other patient, who is still alive, has progressive local re-
currence.
Table 1 lists the number of patients who have devel-
oped distant relapse by nodal subgroup. After a median
follow-up duration of 91.5 months, the crude rate of free-
dom from distant relapse was 39%. The proportion of
patients who were free from distant relapse at 5 years (ie,
excluding three patients who relapsed after 5 years) was
45%. Thirty-two patients (50%) are alive, 22 in the group
of 45 patients (49%) with - 10 involved lymph nodes
and 10 of 19 patients (53%) with - 70% involvement and
fewer than 10 nodes identified (nonsignificant difference).
The 5-year actuarial rate of freedom from distant relapse
was 45% and the 10-year rate was 35% (Fig 1). The 5-
year overall survival rate was 65% and the 10-year rate
was 48% (Fig 1). Nine patients (14%) were alive and
free of disease for > 8 years. The crude rate of survival
was not significantly different by nodal group (Table 1
and Fig 2).
Table 2 lists the results of an analysis of the effect of
age at diagnosis on the risk of distant relapse and survival.
Patients were divided into two groups: age - 50 years
(predominantly postmenopausal) or less than 50 years
(predominantly premenopausal). Of note, 52% of the
study group were older than 50 years. There were no
significant differences in freedom from distant relapse or
survival (Fig 3).
The postsurgical treatment regimen was reasonably
well tolerated. During phase 1, minor delays in treatment
due to toxicity occurred in 19% of patients. Only three
of 64 patients failed to complete the three planned cycles.
Leukopenia was the most common toxicity, but total
WBC counts decreased less than 2.0/jiL in only two pa-
tients. Fifty-three patients (83%) received - 85% of the
planned dose of cyclophosphamide. Approximately 60%
of patients experienced some nausea during this phase,
but this was severe for only two women. There were
no severe reactions to radiotherapy. Moist desquamation
occurred in 20 women (31%), and it was localized and
responded to topical local treatments. The risk of moist




Group No. No. % No. %
10 positive nodes 45 16 36 22 49
- 70% nodes positive (if
< 10 nodes dissected) 19 9 47 10 53
P NS NS
Total 64 25 39 32 50
Abbreviation: NS, not significant.
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Fig 1. Freedom from distant
failure (E, FDF) survival and
overall survival (U, OS) for all
patients. The 5- and 10-year
rates of FDF were 45% (25 pa-
tients at risk) and 35% (2 pa-
tients at risk), and of OS were
65% (36 patients at risk) and
48% (2 patients at risk).
TIME (YEARS)
Fig 2. FDF for patients with ý!
10 positive nodes (45 patients,
El) and < 10 positive nodes (but
- 70% or more involved by car- r
cinoma; 19 patients, U). The 5-
year rate of FDF was 42% for
group 1 (16 patients at risk) and
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Table 2. Crude Rates of Distant Relapse and Overall Survival
by Age at Diagnosis
FDF Surviving Patients
Group No. No. % No. %
< 50 years 31 11 36 16 52
- 50 years 33 14 42 16 48
P NS NS
desquamation was unaffected by treatment protocol.
Fifty-two patients (81%) completed the planned number
of cycles of chemotherapy for phase 3 of the treatment
course. Seven patients (11%) received less than 50% of
the planned dose. Forty women (63%) received > 85%
and 24 women (38%) received 100% of the planned dose
of cyclophosphamide. Concurrent CMF and radiotherapy
as given in protocol 4 did not influence the risk of marrow
suppression. The percentages of cyclophosphamide given
compared with that planned were 77%, 88%, 92%, and
100% for protocols 1 to 4, respectively. Minor delays
due to toxicity occurred for 19 women during phase 3.
Leukopenia was common, but WBC counts of less than
2.0/gL occurred on only four occasions. Sixty-two per-
cent of patients experienced no nausea during this phase
and severe vomiting was rare. Moderate nausea and vom-
Fig 3. FDF for patients aged
< 50 years (n = 31, U) and w
50 years (n = 33, 0). The 5-year
rate of FDF was 43% for younger F
patients and 47% for older pa-
tients (not significant).
iting occurred in 18% of women. Symptomatic pulmonary
pneumonitis occurred in four patients (6%). Arm edema
was documented in 17 patients (27%) and was severe for
eight (13%).
DISCUSSION
In this report, we have updated our experience on the
management of patients with nonmetastatic breast carci-
noma with extensive nodal involvement treated with com-
bined chemotherapy and radiotherapy following mastec-
tomy.' We report high local control rates and moderate
rates of freedom from distant relapse and survival using
a protocol that is associated with acceptable toxicity and
no treatment-related mortality.
There is a consensus that patients found to have > 10
positive nodes following total mastectomy and axillary
dissection have extensive nodal involvement and a poor
prognosis. 23, 25 However, there is no clear definition of
what constitutes extensive nodal involvement if fewer
than 10 nodes are found after an axillary dissection. War-
ren and Tompkins26 found that patients with greater than
50% involvement of identified nodes had a 38% 5-year
disease-free survival rate compared with 19% if all nodes
identified were involved. In this report, we defined exten-
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involvement if fewer than 10 nodes were identified.' Of
note, there was no significant difference in the risk of
distant relapse or overall survival between these two sub-
groups (Table 1).
Adjuvant chemotherapy in standard doses has im-
proved disease-free survival and possibly overall survival
compared with historic and randomized controls. In the
randomized trial of adjuvant CMF chemotherapy follow-
ing mastectomy reported by Bonadonna et al,25 fewer
patients had - 10 or positive nodes (7%) than would have
been predicted from the American College of Surgeon's
survey (14%). This may indicate selective referral of
lower-risk patients to a trial of adjuvant chemotherapy
without radiation therapy. The probability of local recur-
rence was not reported, but patients in both the control
and treated arms had a very poor prognosis, with a 7-year
relapse free survival rate of 11%. A recent nonrandomized
study of 564 patients treated with mastectomy and adju-
vant chemotherapy reported local recurrence rates by
nodal status. 27 At 3 years, patients had an isolated locore-
gional recurrence rate of 22% (> seven nodes positive)
compared with 14% (four to seven nodes positive) and
8% (< three nodes positive) (P < .001). The reported
rates of local recurrence may be low because of short
follow-up times and because local recurrences were not
scored after distant relapse. Of note, the majority of pa-
tients in our study developed local recurrence either con-
currently or after distant relapse. For six of eight patients,
local recurrences were localized, and for two patients,
carcinoma en curaisse was present at last follow-up evalu-
ation or death.
The use of chemotherapy and radiotherapy versus che-
motherapy alone following mastectomy has been studied
in eight randomized trials.5-7,10-14 Most studies are small,
with a median of approximately 200 patients (range, 159
to 1,473). Also, most studies use a cutoff of more or
less than four positive nodes to define extensive nodal
involvement. The small number of patients could mean
that a small, but clinically important difference in survival
may be undetected. All seven studies that reported pat-
terns of relapse showed an increase in disease-free sur-
vival for patients who received adjuvant radiotherapy. A
statistically significant reduction in local recurrence was
found in five studies.5."'14 Four studies7,10,13.14 showed a
significant improvement in disease-free survival by using
a combined modality approach, and the largest study from
Denmark of 1,473 patients also found a significant 5-year
survival advantage.' 4 Follow-up times ranged from less
than 1 year to 9 years. The 5-year actuarial survival rate
was 68% for patients who received adjuvant chemother-
apy and radiotherapy, compared with 63% for patients
who received adjuvant chemotherapy (P = .03). In our
series, most surviving patients were monitored for at least
5 years and the 5-year actuarial rate of overall survival
was 63%.
Limited data are available from randomized trials of
adjuvant chemotherapy for patients with extensive nodal
disease also treated with radiotherapy. One study found,
by subgroup analysis, a significant improvement in 5-
year overall survival for patients with four or more posi-
tive nodes who received postmastectomy chemotherapy
and radiotherapy (54%) compared with patients who re-
ceived adjuvant radiotherapy (35%) or adjuvant chemo-
therapy (46%) (P = 0.01)."0 A study from the Southeast-
ern Cancer Study Group also separately analyzed patients
with four or more positive nodes treated with mastectomy
and adjuvant treatment. After a median follow-up dura-
tion of 10 years, patients who received postmastectomy
radiotherapy and chemotherapy had a survival rate of
55% compared with 46% for patients who received adju-
vant chemotherapy alone (nonsignificant difference).' 3
Table 3 lists previous reports that have published data
for patients with extensive nodal involvement, generally
defined as > 10 involved lymph nodes. Of note, our
results, at a median follow-up time of 91.5 months, are
comparable to those of more recent studies using more
intensive chemotherapy dose regimens with or without
autologous bone marrow transplantation.
Radiotherapy and chemotherapy can be given without
a reduction in hematologic tolerance. 5'28 29 Our study com-
pares favorably with other reports, in which 83% of pa-
tients received >- 85% of the planned dose of cyclophos-
phamide for phase 1 and 63% for phase 2. Symptomatic
pneumonitis occurred in 4% of patients. The combined
modality approach has been well tolerated, with an ac-
ceptable degree of toxicity and no treatment-related mor-
tality. Treatment was well tolerated irrespective of meno-
pausal status.
The concept that more chemotherapy is necessarily bet-
ter has not been clearly established. There is evidence
that a threshold may exist whereby increased toxicity
associated with higher doses of chemotherapy will not be
rewarded by improved tumor outcome.30' 3 However, in
an attempt to improve the results of treatment for this
group of patients, a number of investigators have explored
more dose-intensive chemotherapy regimens. 5", 6 Hudis
et al,15 at the Memorial Sloan-Kettering Cancer Center,
have accrued 45 patients with more than four positive
440
Downloaded from ascopubs.org by University of Queensland on March 16, 2017 from 130.102.082.198
Copyright © 2017 American Society of Clinical Oncology. All rights reserved.
BREAST CANCER: COMBINED CHEMOTHERAPY AND RADIOTHERAPY
Table 3. Previous Studies Including Patients With Extensive Nodal Involvement
% 10 Disease- Overall
No. of Nodes Nodal % Local Free Survival Survival
First Author Year Patients Positive Time of Results Subgroup Adjuvant Treatment Recurrence (%) (%)
Nemoto' 1980 1,088 14.3 60 months > 10 - RT ? 26 28
Donegan3  1978 801 ? 5-24 years > 10 Nil -50 -10 -5
Bonadonna' 1976 9 5.0 10 years act. a 10 CMF ? 11 44
Bonadonno25 1985 58 100 72 months, med a 10 A/CMF ? 60 84
Pisansky27  1993 96 17.0 112 months, med > 7 CFp 22 50t ?
Buzdar3" 1992 283 100 5 years, act 10 A, C, - M V 5 (+ RT), 11 41 56
RT (no RT)
Uematsu3 5  1993 39 17 60 months, act 10 A +/or CMF ± RT 7.7 14 ?
Fowble36  1988 30 40 28 months, med > 8 CMF + RT 3.3 27 ?
Davidson3 7  1992 62 100 40 months a 10 High-dose CAMV ? 53 81
Peters 17  1993 102 (85)* 100 40 months, med - 10 FAC, CPA, cDDP, 6 72 77
BCNU + ABMT +
TAM
Gianni33  1992 85 (48)* 100 21 months, med - 10 High-dose CMV, ? 93 92
CPA, L-PAM +
ABMT
Current study 1994 64 100 60 months, act -10 NC or AC-RT-CMF 12.5 45 65
Abbreviations: C, cyclophosphamide; M, methotrexate; F, fluorouracil; A, doxorubicin; V, vincristine; RT, radiotherapy; CPA, cisplatin; cDDP, carmustine;
ABMT, autologous bone marrow transplant; TAM, tamoxifen; N, mitoxantrone; p, prednisone; med, median; act, actuarial; BCNU, carmustine.
'Number eligible.
nodes to a dose-intensive chemotherapeutic regimen of
cyclophosphamide with granulocyte colony-stimulating
factor after doxorubicin. After less than 12 months of
follow-up evaluation, half have completed chemotherapy
and remain relapse-free. Twenty separate hospital admis-
sions were required for 11 patients because of complica-
tions, but there were no treatment-related deaths. A study
from the Johns Hopkins University examined the value
of a 16-week dose-intensive regimen for 53 patients with
- 10 positive nodes. At a median follow-up time of 21
months, there were 13 relapses with a projected 3-year
actuarial disease-free survival rate of 61%. Seven patients
(13%) required hospitalization, but there were no treat-
ment-related deaths." In our study, only two patients re-
quired hospitalization during treatment, and the 3-year
disease-free survival rate was 60%. This is comparable
given that all surviving patients were monitored for a
minimum of almost 5 years and the median follow-up
duration was 91.5 months.
High-dose chemotherapy and autologous bone marrow
transplantation has also been examined for this group of
patients. However, it is important to note that patients are
highly selected for this approach, often on the basis of
general fitness and younger age.32 The Milan group of-
fered this treatment to 85 patients, but 37 (44%) either
refused treatment or could not undergo treatment for lo-
gistic reasons. All patients were aged < 55 years, com-
pared with 70% in this age group in our study. Forty-
eight patients with - 10 positive nodes were treated. The
2-year actuarial relapse-free survival rate was 93% with
one (2%) treatment-related death.33 Peters et al"8 at Duke
University treated a similar group of high-risk patients
with high-dose cyclophosphamide, cisplatin, and carmus-
tine with autologous bone marrow transplantation as con-
solidation after standard-dose adjuvant chemotherapy. Of
note, 95% of patients were - 50 years of age. Further-
more, patients were highly selected. Investigations in-
cluded computed tomography of the head, chest, abdo-
men, and pelvis; bone scans and bilateral bone marrow
aspirations; and biopsies. With a median follow-up dura-
tion of 3.3 years, the disease-free survival rate was 72%
and overall survival rate 77%. Treatment-related mortal-
ity was high at 12%. Our study showed comparable results
at similar follow-up times, without treatment-related mor-
tality, and was used for both premenopausal and post-
menopausal women.
We conclude that patients with extensive nodal disease
after mastectomy treated with postmastectomy chemo-
therapy and radiotherapy achieve comparable high local
control, disease-free, and overall survival rates to more
intensive chemotherapy regimens with or without bone
marrow transplantation. As such, there has to be a reason-
able prediction from efficacy and cost-effective analysis
of current studies that higher survival rates will be ob-
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tained using these high-dose chemotherapy approaches adjuvant chemotherapy and radiotherapy similar to that
given their high cost, significant morbidity, and risk of used in our study.
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